• 6 ways to build a pharmaceutical culture centered on patient safety

    Patient safety is often viewed from a lens inside medical center and hospital walls, but the leadership of pharmacists and decisions made along the medical supply chain also play a role, Londa Ritchey, the quality director at PharmaLex wrote in a May 25 article for PharmaPhorum.
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • Amoxicillin shortage expected to continue into June

    The ongoing amoxicillin shortage is projected to continue into June, according to a May 22 update from the American Society of Health-System Pharmacists.
  • New Jersey drug company to lay off 94

    PTC Therapeutics, a drug development company based in South Plainfield, N.J., said it will lay off 94 employees at its corporate office by Aug. 21, according to a notice filed in the state. 
  • Paxlovid becomes 1st approved COVID-19 pill

    The FDA granted Pfizer's popular COVID-19 antiviral treatment, Paxlovid, full approval on May 25.
  • Amid cancer drug shortage, 'every drop of chemotherapy' used at hospitals

    Some hospitals are scraping vials to offer enough cancer drugs for their patients as the U.S. faces about two dozen chemotherapy shortages.
  • Cuban picks up 5 more brand-name drugs

    Billionaire and Shark Tank investor Mark Cuban will soon start selling five Pfizer brand-name drugs through his pharmaceutical company, Mark Cuban Cost Plus Drug Co. 
  • Why big PBMs form GPOs

    Following the Federal Trade Commission's expanded probe into pharmacy benefit managers and their group purchasing organizations, Drug Channels listed five possible reasons why PBMs create GPOs.
  • Cuban's pharmacy drops 18 prices

    Mark Cuban Cost Plus Drug Co. lowered prices for 18 drugs May 23, according to a company tweet. 
  • RSV, pneumonia drug falls into shortage

    There is not enough supply for usual ordering of ribavirin inhalation solutions, a drug for severe pediatric pneumonia cases caused by respiratory syncytial virus, according to a May 23 post from the American Society of Health-System Pharmacists. 
  • FDA approves drug for hospital-acquired pneumonia

    On May 23, the FDA approved a new drug intended to treat hospital-acquired pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus, a critical bacterial pathogen. 
  • AHA, ASHP oppose 340B bill set for markup

    The American Hospital Association and American Society of Health-System Pharmacists, along with four other groups, recently sent a letter to the House Energy and Commerce Committee's Health Subcommittee opposing two bill amendments that would affect 340B hospitals and stakeholders.
  • Moderna buys biomanufacturing plant in Massachusetts; project expected to cost $322M

    Moderna has purchased a new biomanufacturing facility in Marlborough, Mass., which will be designated for mRNA manufacturing. It is anticipated to open in September 2024, according to an April 28 report from the Worcester Business Journal. 
  • Ozempic pill results in 15% weight loss: Novo Nordisk

    A pill version of Ozempic (semaglutide), a Type 2 diabetes drug in high demand for its off-label use for weight loss, resulted in 15.1 percent weight loss among phase 3 study participants. 
  • 30 OTC health products recommended by pharmacists

    In U.S. News' newest over-the-counter medicine and health products ranking, the news organization collaborated with The Harris Poll to determine what 350 pharmacists recommend among more than 700 products. 
  • Top PBMs by 2022 market share

    One pharmacy benefit manager makes up one-third of the market, according to a May 23 report from Drug Channels. 
  • Teva to cut back on generic manufacturing

    Teva Pharmaceuticals said it will shrink some of its generic drug manufacturing as the Israel-based drugmaker reports $20.7 billion in debt. 
  • ASHP launches national pharmacy technician group

    The American Society of Health-System Pharmacists has announced the inaugural launch of a national membership organization aimed at supporting and advocating for policies that advance the role of pharmacist technicians in patient care.
  • FDA approves 1st drug for rare skin condition

    The FDA on May 19 approved the first drug to treat patients with dystrophic epidermolysis bullosa — a rare genetic disorder that causes fragile skin and persistent sores. 
  • Optum COO moves to Corewell Health pharmacy position

    Corewell Health, based in Grand Rapids and Southfield, Mich., named Jason McCarthy, PharmD, as its next chief pharmacy officer May 17. 
  • What could happen if Medicare covered weight loss drugs?

    A 2003 law prohibits Medicare Part D from covering weight loss drugs, but if that changes, this class of popular medications could cost Medicare tens of billions, the KFF reported May 18. 

Featured Whitepapers

Featured Webinars